Amendment 12: DRIVe EZ Broad Agency Announcement

Office of Biomedical Advanced Research and Development
Authority (BARDA) Division of Research, Innovation & Ventures

(DRIVe)

Amendment 012 Issuance for Easy Broad Agency Announcement

(EZ-BAA) BAA-22-100-SOL-00003

The purpose of this Amendment is the following:
1) Update the closing date for the following Area of
Interest (AOI):
AOI #16: Lab at Home
2) Update the closing date for the following Area of
Interest (AOI):
AOI #17: Digital MCMs
3) Update the closing date for the following Area of
Interest (AOI):
AOI #19: Healing Lungs
4) Revise the following Area of Interest (AOI):
AOI #16: Lab at Home

5) Add the following Area of Interest (AOI):
AOI #26: Agnostic Diagnostic

INTRODUCTION AND OVERVIEW INFORMATION

A. Development Opportunity Objective:

Under this Amendment, DRIVe is doing the following:
1)

Updating the closing date for the following research Area of Interest (AOI): AOI #16: Lab at Home

2)

Updating the closing date for the following research Area of Interest (AOI): AOI #17: Digital MCMs

3)

Updating the closing date for the following research Area of Interest (AOI): AOI #19: Healing Lungs

4)

Revising the following research Area of Interest (AOI): AOI #16: Lab at Home
We are seeking abstract submissions for the following AOI: EZ BAA AOI #16: Lab at Home

DRIVe is seeking proposals to develop novel instrumentation-based platform technologies for ondemand, simultaneous detection of multiple biochemical health markers at the point of need. The goal is to obtain quantitative information about patients’ health status at the point of need, avoiding the long sample-to-answer times and personnel training requirements of traditional central laboratory testing that can lead to delays in receiving care. Such platforms could remove existing complications patients face in seeking remote diagnoses by physicians, including sample shipping or travel to sample collection sites. Enabling testing at the point of need could greatly improve the efficiency and accessibility of tools for infection detection, chronic disease management, clinical trial management etc., leading to a healthier population with reduced healthcare costs.
The goal of projects funded through this AOI is feasibility demonstration of enabling technologies that allow for simultaneous detection and quantification of several host biochemical markers in a multiplexed manner.

The instrumentation / platform technologies developed through this program are primarily intended for